Lixte Biotechnology company info

What does Lixte Biotechnology do?
Lixte Biotechnology (NASDAQ:LIXT) is a biotech company dedicated to developing innovative treatments for cancer. It is currently traded on the NASDAQ stock exchange under the ticker symbol LIXT. The company's operations focus on discovering and advancing a portfolio of compounds that promise to play significant roles in cancer therapy, notably by targeting pathways critical for the growth and survival of cancer cells. Their projects range from early-stage research to clinical development, with an emphasis on creating drugs that can improve outcomes for patients facing various types of cancer. Lixte Biotechnology’s objectives emphasize innovation in oncology drug development, with the ultimate goal of bringing new therapeutic options to market that can offer better efficacy and fewer side effects than existing treatments.
Lixte Biotechnology company media
Company Snapshot

Is Lixte Biotechnology a public or private company?

key
Ownership
Public

How many people does Lixte Biotechnology employ?

people
Employees
3

What sector is Lixte Biotechnology in?

pie chart
Sector
Health Care

Where is the head office for Lixte Biotechnology?

location pin
Head Office
East Setauket, United States

What year was Lixte Biotechnology founded?

founded flag
Year Founded
2005
What does Lixte Biotechnology specialise in?
/Cancer Therapeutics /Drug Discovery /Clinical Trials /Biotechnology Innovator /Neurology Solutions /Oncology Research

What are the products and/or services of Lixte Biotechnology?

Overview of Lixte Biotechnology offerings
Lead product LB-100, a small molecule for treating solid tumors and hematologic cancers.
Collaboration on clinical trials for LB-100 in combination with traditional cancer therapies.
Research into the mechanisms of action of protein phosphatase inhibitors for improved cancer treatments.
Exploration of LB-100’s potential in enhancing the effectiveness of immunotherapies.
Investigations into the genetic profiles that predict sensitivity to LB-100 for personalized cancer therapy.

Who is in the executive team of Lixte Biotechnology?

Lixte Biotechnology leadership team
  • Mr. Bastiaan  van der Baan M.Sc.
    Mr. Bastiaan van der Baan M.Sc.
    President, CEO & Chairman of the Board of Directors
  • Mr. Robert Neal Weingarten
    Mr. Robert Neal Weingarten
    VP & CFO
  • Mr. Eric J. Forman J.D.
    Mr. Eric J. Forman J.D.
    VP & COO
  • Dr. James S. Miser M.D.
    Dr. James S. Miser M.D.
    Chief Medical Officer